Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1. (Original) A polypeptide comprising a W-rich peptide and a conservative variant or functional fragment thereof.
- 2. (Original) The polypeptide according to claim 1, which is from 4 to 15 amino acids long.
- 3. (Original) The polypeptide according to claim 2, which is from 4 to 10 amino acids long.
- 4. (Original) The polypeptide according to claim 3, which is from 4 to 7 amino acids long.
- 5. (Original) The polypeptide according to claim 4, which is 6 amino acids long.
- 6. (Currently amended) The polypeptide according to claim 1, which is represented by SEQ ID NOS:4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 35-or 7.
- 7. (Original) The polypeptide according to claim 6, which is represented by SEQ ID NOS:4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.
- 8. (Original) The polypeptide according to claim 7, which is represented by SEQ ID NOS:4, 5, 6, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27.
- 9. (Original) The polypeptide according to claim 8, which is represented by SEQ ID NOS:4, 16, 17, 18, 19, 20, 21, 22, 23 or 25.
- 10. (Original) The polypeptide according to claim 9, which is represented by SEQ ID NOS:4, 16, 18, 20, 21 or 22.
- 11. (Original) The polypeptide according to claim 10, which is represented by SEQ ID NOS:4 or 16.
- 12. (Original) A W-rich peptide mimic.

- 13. (Original) A method of preventing inflammation in a subject comprising the steps of: providing an inflammation preventing effective amount of the polypeptide according to claim 1 or a W-rich peptide mimic thereof to the subject in need thereof.
- 14. (Currently amended) A The method of treating arthritis in a subject comprising the steps of: providing an inflammation preventing effective amount of the polypeptide according to claim 1 or a W-rich peptide mimic thereof to the subject in need thereof according to claim 13, wherein the inflammation is arthritis.
- 15. (Original) A method of treating an auto-immune disease in a subject comprising the steps of: providing a therapeutically effective amount of the polypeptide according to claim 1 or a W-rich peptide mimic thereof to the subject in need thereof.
- 16. (Original) A method of preventing binding of $A\beta42$ to human neutrophils comprising contacting the neutrophil with the polypeptide according to claim 1 or a W-rich peptide mimic thereof.
- 17. (Original) A method of treating Alzheimer's Disease comprising administering a therapeutically effective amount of the polypeptide according to claim 1 or a W-rich peptide mimic thereof to a subject in need thereof.
- 18. (Original) A method of identifying a FPR class receptor antagonist comprising the steps of: providing a cell having a FPR class receptor; contacting the cell with a candidate antagonist compound; and identifying the candidate antagonist compound as an antagonist compound if the candidate binds to a FPR class receptor and inhibits its activity.
- 19. (Original) The method according to claim 18, wherein the FPR class receptor is a FPRL1.
- 20. (Original) A pharmaceutical composition comprising the polypeptide according to claim 1 or W-rich peptide mimic thereof.